Analytical Development, Pharmaceutical Science, Baxalta Innovations GmbH, a Takeda Company, Industriestrasse 67A-1221 Vienna Wien, Austria.
R&D Plasma Derived Therapies, Baxalta Innovations GmbH, a Takeda Company, Austria.
J Pharm Biomed Anal. 2022 Feb 5;209:114476. doi: 10.1016/j.jpba.2021.114476. Epub 2021 Nov 23.
Functionally active alpha-antitrypsin (AAT) is measured predominantly with a chromogenic elastase inhibition assay, where the concentration of AAT activity inversely correlates with the levels of residual elastase. This standard assay has moderate sensitivity as it hardly allows the measurement of samples containing less than 10 µg of functionally active AAT per mL. To overcome this drawback, we developed a new assay format for the measurement of functionally active AAT, which we termed the elastase complex formation immunosorbent assay (ECFISA). The ECFISA uses plate-bound, still proteolytically active elastase, which attacks functionally active AAT under irreversible formation of a stable stochiometric 1 + 1 complex. This complex is then detected and measured by an anti-AAT peroxidase conjugate. Using three different approaches for the preparation of functionally inactive AAT - heating, oxidation, and complex formation with elastase - we confirmed beyond doubt that the ECFISA exclusively measures functionally active AAT and that these measurements are unimpaired by the presence of high concentrations of functionally inactive AAT. Studies addressing the coating procedure demonstrated that adequate and robust conditions had been defined for this essential first step of the ECFISA. Possible interference caused by the presence of important plasma proteinase inhibitors in the test samples could be excluded for the most abundant inhibitors. Even a 1.5-times molar excess of alpha-macroglobulin over AAT was shown to have no impact, which is not the case for a conventional chromogenic activity assay. Functional activities determined with the ECFISA and validated chromogenic elastase inhibition assay matched well with a mean absolute bias of 0.64% calculated for the 25 samples measured. The results of the bioanalytical assay validation complied with the acceptance criteria for ligand-binding assays as given by current guidelines on validation of bioanalytical methods. Overall, the data obtained demonstrated the ECFISA as an accurate, precise, selective, and very sensitive method for AAT activity measurement at low levels previously inaccessible for direct measurement.
功能活性的α-1 抗胰蛋白酶(AAT)主要通过显色弹性酶抑制测定法进行测量,其中 AAT 活性浓度与剩余弹性酶的水平呈反比。该标准测定法的灵敏度适中,因为它几乎无法测量每毫升含有少于 10μg功能活性 AAT 的样品。为了克服这一缺点,我们开发了一种新的用于测量功能活性 AAT 的测定方法,我们将其命名为弹性酶复合物形成免疫吸附测定法(ECFISA)。ECFISA 使用板结合的、仍然具有蛋白水解活性的弹性酶,该酶在不可逆地形成稳定的化学计量 1+1 复合物的情况下攻击功能活性 AAT。然后通过抗 AAT 过氧化物酶缀合物检测和测量该复合物。使用三种不同的方法制备无功能活性的 AAT - 加热、氧化和与弹性酶形成复合物 - 我们毫无疑问地证实,ECFISA 仅测量功能活性 AAT,并且这些测量不受高浓度无功能活性 AAT 的影响。针对包被程序的研究表明,已经为 ECFISA 的这个基本的第一步定义了充分和稳健的条件。可以排除测试样品中存在的重要血浆蛋白酶抑制剂造成的可能干扰。即使是 AAT 的α-巨球蛋白摩尔过量 1.5 倍,也不会产生影响,这与常规的显色活性测定法不同。用 ECFISA 确定的功能活性并经验证的显色弹性酶抑制测定法的吻合度很好,对于测量的 25 个样本,平均绝对偏差为 0.64%。生物分析测定验证的结果符合当前生物分析方法验证指南中关于配体结合测定的验收标准。总的来说,所获得的数据证明 ECFISA 是一种准确、精密、选择性和非常灵敏的方法,可用于测量以前无法直接测量的低水平的 AAT 活性。